What is the study about?
The COMP-006 study is trying to find out whether two initial administration doses of COMP360, given with psychological support, can improve depressive symptoms for those patients who have treatment-resistant depression (TRD).
Who can take part?
We are looking for adult participants, over the age of 18, who have been diagnosed with major depression (single of recurrent episodes) and are experiencing treatment-resistant depression.
Other criteria will need to be met to confirm a participant’s eligibility for the COMP-006 study.
What is involved?
The study lasts up to 62 weeks, includes 3 parts, (Parts A, B and C). There will be two doses administration of COMP-006 in part A, one dose in Part B for eligible participants and one open label dose in Part C.
Treatment and psychological therapy will take place at St Pancras Clinical Research Centre and screening and follow up visits will take place at Two Bridges R&D. Transport will be reimbursed to participants.